Dosages of melphalan / cytarabine:
The median dosage of melphalan was 1x40 mg/m² with a range of 1x20 mg/m² to 2x60 mg/m². The reason for the low dosage of melphalan in one case was a high cumulative toxicity prior to the melphalan / cytarabine therapy. A very aggressive form of AML was the reason for choosing a higher dosage of melphalan. The median dosage of cytarabine was 3 x 1 g/m² with a range of 5 x 100 mg/m² to 4 x 1 g/m². The reason for adopting a low dosage of cytarabine was high cumulative toxicity prior to the melphalan / cytarabine therapy. In this case cytarabine was given as a continuous infusion. Four patients received additional intrathecal chemotherapy. One patient received additional daratumomab. In this case the underlying disease was a CD38-positive T-lymphoblastic lymphoma. One patient with a common ALL received additional blinatumomab and one patient with AML received additional venetoclax. For further information concerning the melphalan / cytarabine regimen see Table 2.